<code id='13182EF7E0'></code><style id='13182EF7E0'></style>
    • <acronym id='13182EF7E0'></acronym>
      <center id='13182EF7E0'><center id='13182EF7E0'><tfoot id='13182EF7E0'></tfoot></center><abbr id='13182EF7E0'><dir id='13182EF7E0'><tfoot id='13182EF7E0'></tfoot><noframes id='13182EF7E0'>

    • <optgroup id='13182EF7E0'><strike id='13182EF7E0'><sup id='13182EF7E0'></sup></strike><code id='13182EF7E0'></code></optgroup>
        1. <b id='13182EF7E0'><label id='13182EF7E0'><select id='13182EF7E0'><dt id='13182EF7E0'><span id='13182EF7E0'></span></dt></select></label></b><u id='13182EF7E0'></u>
          <i id='13182EF7E0'><strike id='13182EF7E0'><tt id='13182EF7E0'><pre id='13182EF7E0'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:7
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Parents surprise family after baby discharged from NICU after 170 days
          Parents surprise family after baby discharged from NICU after 170 days

          1:44AfterbabyEliwasdischargedfromthehospital,hisparents,TylerandIrveEdmond,drove18hoursfromNorthCaro

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          The U.S. needs a new definition of substance use “recovery”

          Adobe“WhenIuseaword,”oneof19thcenturyBritishauthorandmathematicianLewisCarroll’scharactersoncesaid,“